Invesco NASDAQ 100 ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? Invesco NASDAQ 100 ETF trades at $308.94 (market cap $113.40B), while Roivant Sciences Ltd. Common Shares trades at $34.76 (market cap $24.72B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 4.6× Roivant Sciences Ltd. Common Shares's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Roivant Sciences Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 54 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| QQQM | ROIV | |
|---|---|---|
Market Cap | $113.40B | $24.72B |
Volume | 2,866,236 | 6,279,442 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $41.81 |
52-Week Low | $229.87 | $16.04 |
Typical Hold Time | 54 Days | 0 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $308.42, down 1.15% on the day, while maintaining a bullish technical outlook with strong moving average support. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026, signaling confidence in the Nasdaq-100 exposure.
The ETF offers pure Nasdaq-100 exposure with competitive fees, though investors should be aware of concentration risk in technology stocks and potential tax implications of distributions. Technical indicators suggest near-term support at $305 with resistance at $311, while institutional accumulation supports the bullish case for long-term growth investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →